What is the treatment for relapsed or refractory PTCL?
No consensus exists on the best therapeutic strategy for relapsed/refractory PTCL. Relapsed refers to disease that reappears or grows again after a period of remission.
Refractory is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.
Since 2009, there have been three agents approved for people with PTCL by the United States Food and Drug Administration:
- Pralatrexate (Folotyn)
- Romidepsin (Istodax)
- Belinostat (Beleodaq)
For more information on these drugs, visit the FDA Drug Updates page.
For patients with relapsed or refractory PTCL, the National Comprehensive Cancer Network guidelines recommend clinical trials. If a clinical trial is not available, combination therapies or single-agent drugs may be prescribed. In addition, some patients may receive a stem cell transplant (SCT).
Novel approaches to the treatment of PTCL in the relapsed or refractory setting are under investigation. For information about clinical trials, please contact the Lymphoma Research Foundation's Helpline at (800) 500-9976 or email@example.com.